XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Convertible Preferred Shares and Shareholders' Equity (Deficit) (Details)
$ / shares in Units, $ in Thousands
Mar. 22, 2022
USD ($)
Vote
$ / shares
Mar. 31, 2023
$ / shares
shares
Mar. 20, 2023
$ / shares
shares
Mar. 16, 2023
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
Asset Acquisition [Line Items]          
Number of Class A ordinary shares on conversion     267,939    
Class A ordinary shares, par value per share | $ / shares   $ 0.0001 $ 0.0001 $ 0.0001  
Exchange ratio for Class A ordinary shares pursuant to the business combination   108.083 108.083 108.083  
Class A ordinary shares authorized   300,000,000   300,000,000 1,884,649
Preferred shares, shares authorized   1,000,000   1,000,000 0
Preferred shares, par value per share | $ / shares   $ 0.0001   $ 0.0001 $ 0.0001
Preferred shares, shares issued   0     0
Preferred shares, shares outstanding   0     0
Series A-1 convertible preferred shares, minimum gross aggregate subscription with respect to new Ordinary Shares required for conversion | $ $ 50,000        
Series A-1 convertible preferred shares, dividends declared | $ $ 0        
Series A-1 convertible preferred shares, liquidation preference per share | $ / shares $ 131        
Series A-1 convertible preferred shares, number of votes per share | Vote 1        
Legacy Zura          
Asset Acquisition [Line Items]          
Class A ordinary shares, par value per share | $ / shares     $ 0.001    
License Agreement and a Series A-1 Subscription and Shareholder's Agreement with Pfizer [Member]          
Asset Acquisition [Line Items]          
Anti-Dilution, percentage of ownership interest to be maintained 18.00%        
Minimum value of capital to be raised for not being subject to anti-dilution | $ $ 30,000